Deletion requests do federate
in my experience - not very well. i have received answer to deleted comment more than once.
Deletion requests do federate
in my experience - not very well. i have received answer to deleted comment more than once.
good luck convincing communists to give back what is not theirs 😂
but really, lemmy is not good for this. your comment exists in multiple physical copies on every instance from which someone interacted with the thread. it is prime example of once it is out there, it is out there forever…
Jesus, I can’t imagine just coming out and saying this like it’s not fucking deranged to charge people more for WATER during a heat wave.
and if there is a fire, we can raise prices of fire extinguishers, how cool is that?
the truth must be told: Firefox is not as optimized as Chrome
what are you talking about? my desktop pc is amd fx4300. definition of old and subpar - https://i.imgur.com/WBm5Ub1.png - and i have 313 open tabs right now.
granted, that is slightly more affected by memory, before i updated from 8 to 32 gb recently, it was admittedly slightly more sluggish.
but at the same time normal people don’t really have 300 open tabs at once and also you have to ask what is the threshold where you are willing to sacrifice your privacy for slight speed increase.
do you have some numbers to support that speed difference, or is it just your feeling, or anecdote that is being passed around and everyone repeats it and everyone believes it, because everyone says so?
what i don’t get is all the people complaining about google and at the same time using their browser…
i believe that trying to steer masses away from chrome would be more useful in the long run than trying to make it work
Do businesses in Turkey not make sure people can do the job
i would imagine they do and checking that applicant has proper education is probably big part of that 😆
isn’t that a service already paid for
and that’s why it is a fraud, someone (state) pays for your education and you are scamming him.
deleted by creator
we are not going to ignore lunatic who thinks cheating is normal. he is perpetrating fraud worth thousands of dollars; first in tuition, then in future earnings.
would you like to be operated on by a surgeon who passed the school thanks to ai? would you like to live on a 20th floor of a building designed by such structural engineer?
its a valid question.
no, it is not.
do you really think that article talking about number of ordered planes suddenly switched to number of spare parts? does that sound logical to you? if you don’t recognize such obvious sarcasm, you really shouldn’t try to deliver burns to others, you’ll just burn yourself in the process.
https://en.wikipedia.org/wiki/List_of_Boeing_737_MAX_orders_and_deliveries
long story short: the numbers mean whole aircraft. i hope it is simple enough for you.
Not sure if this is serious.
if you are really not sure whether this:
They could be mainly orders for extra bolts.
is serious, then i recommend to not attempt crossing a street without supervision 😜
yeah, because in the world of audio/video content, who would care about quality of sound, right?
and even if people would actually not care, it still doesn’t mean that someone won’t be able to sell it to them.
If your keyboard was actually working, you pressed a key. If it was not working, you went to get new keyboard. What is “not thought through” about that?
Their point
oh geez, thank you for explaining someone else’s point, you must be quite an insider into their thoughts 😂
was that they never “found out”
that is not what was said
why would you need or want to be that precise about your language
you need to be precise with your language because that is what allows us to communicate ideas to each other and logic through arguments, eventually accepting or refuting them.
for example you can call these two strawberry, and nuclear submarine, but it is going to seriously hinder your communication with others, because that is now what is commonly understood under these terms.
you can see it in the comment we are discussing. because i read the implication original commenter tried to make as it never happened to me => it is not a problem that needs to be addressed.
which is incorrect implication in itself, but more importantly, as i pointed out, the premise of the implication is flawed.
unfortunately czechs dropped from 3 to just 1 seat 😒
so, all hopes on her. but definitely no pressure 😂
i mean, people have innovated in the areas they care already
so you are saying that all the innovation and research should be stopped, because if we care about any specific problem, it is already solved, and if it isn’t, it is proof we don’t care? 😆
that… is not how it works.
and unfortunately czech pirate representatives dropped from three to one :(
Not once have I encountered a trans person on a dating app who wasn’t 100% transparent about it.
…that you know of. not defending bigots or bullying, but that statement doesn’t make sense.
So I am going to sit down and the screen will be full of penis enlargement pills? What will all the hot singles in the area think?
Sure, the FDA could go against the recommendation
narrator: it did not, in fact, go against the recommendation…
F.D.A. Panel Rejects MDMA-Aided Therapy for PTSD
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
By Andrew Jacobs June 4, 2024
An independent advisory panel of the Food and Drug Administration rejected the use of MDMA-assisted therapy for post-traumatic stress disorder on Tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as Ecstasy.
Before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, Lykos Therapeutics. Many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given MDMA, also known by the names of Ecstasy or molly.
The panel voted 9-2 on whether the MDMA-assisted therapy was effective, and voted 10-1 on whether the proposed treatment’s benefits outweighed its risks.
Other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. A case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds.
Many of the committee members said they were especially worried about the failure of Lykos to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well-being.
“I absolutely agree that we need new and better treatments for PTSD,” said Paul Holtzheimer, deputy director for research at the National Center for PTSD, a panelist who voted no on the question of whether the benefits of MDMA-therapy outweighed the risks.
“However, I also note that premature introduction of a treatment can actually stifle development, stifle implementation and lead to premature adoption of treatments that are either not completely known to be safe, not fully effective or not being used at their optimal efficacy,” he added.
While the vote is not binding on the F.D.A., the agency often follows the recommendations of its advisory panels. A final decision by the agency is expected in mid-August.
MDMA, or methylenedioxymethamphetamine, also sometimes referred to as midomafetamine is a synthetic psychoactive drug that fosters self-awareness, feelings of empathy and social connectedness.
The illegal drug is listed as a Schedule I substance, defined as having no accepted medical use and a high potential for abuse. Should it win F.D.A. approval, federal health authorities and Justice Department officials would have to follow certain steps to downgrade the drug’s listing, much like the process now underway with cannabis.
The D.E.A. might also set production quotas for the drug ingredients, as it does with stimulant medications used to treat ADHD.
With the panel’s focus on such topics as “euphoria,” “suicidal ideation” and “expectation bias,” the daylong session on Tuesday demonstrated the nuances and complexities facing regulators as they grapple with the terra incognita of a therapy that only recently entered mainstream psychiatry after the nation’s decades-long war on drugs.
An added wrinkle: the F.D.A. is a regulator of medications. It does not regulate psychotherapy and has not evaluated drugs whose efficacy is tied to talk therapy.
If approved, MDMA-assisted therapy would be the first new treatment for PTSD in nearly 25 years. The condition, which affects some 13 million Americans, has been implicated in the outsized suicide rates among military veterans, whose suffering has galvanized lawmakers from both parties and prompted a sea change in public attitudes about therapies reliant on psychedelic compounds.
According to the studies submitted by Lykos, patients who received MDMA plus psychotherapy reported significant improvements in their mental health. The most recent drug trial found that more than 86 percent of those who took MDMA achieved a measurable reduction in severity of their PTSD symptoms.
About 71 percent of participants improved enough that they no longer met the criteria for a diagnosis. Of those who took the placebo, 69 percent improved and nearly 48 percent no longer qualified for a PTSD diagnosis, according to the submitted data.
The questions, concerns and evident skepticism voiced by the 10-member panel echoed those raised by agency staff members, who last week issued a briefing document aimed at helping the panel evaluate the efficacy and potential adverse health effects of MDMA therapy.
In her opening remarks, Dr. Tiffany Farchione, director of the F.D.A.’s division of psychiatry, noted the regulatory challenges posed by MDMA, saying “we’ve been learning as we go along.” But in her testimony and in staff documents, she and other agency officials repeatedly noted that the overall study results were significant and lasting.
“Although the application presents a number of complex review issues, it does include two positive studies in which participants in the midomafetamine arm experienced statistically significant and clinically meaningful improvement in their PTSD symptoms,” she said. “And that improvement appears to be durable for at least several months after the end of the acute treatment period.”
Much of the criticism about Lykos’s study designs focused on so-called functional unblinding, a problem that affects many studies involving psychoactive compounds. Although the roughly 400 patients who took part in the studies were not told whether they had received MDMA or a placebo, to reduce the odds of bias in the results, the vast majority were acutely aware of any altered state of mind, leading them to correctly guess which study arm they were enrolled in.
The F.D.A., which worked with Lykos to design the trials, has acknowledged shortcomings in the study designs and recently issued new guidance to address the issues facing psychedelic researchers.
A number of other critical voices emerged in recent months. They include the Institute for Clinical and Economic Review, a nonprofit that examines the costs and effectiveness of medications, which issued a report calling the effects of the treatment “inconclusive” and questioning Lykos’s study results.
Other organizations, like the American Psychiatric Association, have not opposed approval outright, but have called on the F.D.A. to mitigate any potential negative consequences by crafting rigorous regulations, strict prescribing and dispensing controls, and close monitoring of patients.
The F.D.A. staff analysis recommended that approval should be contingent on restricted health care settings, monitoring of patients and diligent reporting of adverse events.
Just before they voted on Tuesday, the advisory panel heard from more than 30 speakers who offered starkly divergent views on the application.
Several critics focused on Rick Doblin, a veteran psychedelics advocate who in 1986 founded the Multidisciplinary Association for Psychedelic Studies, the nonprofit organization that filed the original application for MDMA-assisted therapy with the F.DA. The organization later created a for-profit entity that earlier this year became Lykos.
Brian Pace, a lecturer at Ohio State University, described the company applying for approval as a “therapy cult” and criticized Mr. Doblin’s public comments highlighting his zeal for psychedelics, including a belief that legalizing and regulating them would bring about world peace.
But the majority of those who spoke in favor of the application offered deeply personal accounts of how MDMA-therapy had largely quieted the symptoms of their PTSD.
Among them was Cristina Pearse, who said she suffered from PTSD after being sexually assaulted when she was 9. Over the years, she said she had been prescribed a litany of psychiatric medications and at one point she attempted suicide.
MDMA therapy, she said, changed her life. “What used to feel like a tsunami of overwhelming panic was now merely a puddle at my feet,” said Ms. Pearse, who started an organization that helps women recovering from trauma.
She ended her testimony by urging the F.D.A. to approve the application.
“How many more people need to die before we approve an effective therapy?” she asked. “As you weigh the risk, please keep in mind that this therapy can save many lives. I lost most of my life to this disease. I’m grateful to reclaim it now. But I wish this was an approved medication decades ago.”
Rustdesk